ElaineM
10-28-2010, 03:42 PM
This is from ibcresearch.org.
This month we want to bring to your attention an international clinical trial specifically for inflammatory breast cancer. While there are limited sites in the U.S. still recruiting, the study started in 2007, it is important that adequate numbers accrue to the trial so the value of the new compound, pazopanib, can be evaluated. Clinical trial data is essential if there is to be evidenced based data to guide treatment of inflammatory breast cancer.
Pazopanib Plus Lapatinib Compared to Lapatinib Alone in Subjects with Inflammatory Breast Cancer is a phase III, double blind trial. A phase III trial is designed to study safety and efficacy. "The double blind part of the study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with inflammatory breast cancer whose tumorsoverexpress the ErbB2 protein (Her2/neu). There is also an Open-label pazopanib arm to this study designed to test whether pazopanib given alone and lapatinib given alone would be safe and effective to treat patients with inflammatory breast cancer."
Currently there are just two sites in the U.S. recruiting for the trial, and an additional site is pending. To study the inclusion/exclusion criteria and available sites for this trial (NCT00558102) visit: ClinicalTrials.gov. (http://r20.rs6.net/tn.jsp?llr=rpzyw687&et=1103828849689&s=3451&e=001v52O4DI7Y8B9N1cpMA73MiOwVUPNU0DDvPvM7ZhsaFLxU fbj8IVG8rH6rh_Z5pvCvcWajxzDLmUVOYvEmfN-brFzlNm_N3jaTkRaTQvp8hJ0Jii1hgLj3sSS1u2XpcOnQnp5Oa nRgQLh9NyBp6HWPFAdR3nH-vKDHYVOSIKOWRz3QY2QaOJUaWmkUFuhrnTJNxzCgstDnqhon7l kLUnZeN1oSckMrkkfj9PA1R2SfEgrD5XIEVyDP-Z_xZlTs9l3lDMt1tlu2DWBee8nhC_5tQ==)
**The above is informational only and should not be considered a recommendation or endorsement of any specific clinical trial by the Inflammatory Breast Cancer Research Foundation.
This month we want to bring to your attention an international clinical trial specifically for inflammatory breast cancer. While there are limited sites in the U.S. still recruiting, the study started in 2007, it is important that adequate numbers accrue to the trial so the value of the new compound, pazopanib, can be evaluated. Clinical trial data is essential if there is to be evidenced based data to guide treatment of inflammatory breast cancer.
Pazopanib Plus Lapatinib Compared to Lapatinib Alone in Subjects with Inflammatory Breast Cancer is a phase III, double blind trial. A phase III trial is designed to study safety and efficacy. "The double blind part of the study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with inflammatory breast cancer whose tumorsoverexpress the ErbB2 protein (Her2/neu). There is also an Open-label pazopanib arm to this study designed to test whether pazopanib given alone and lapatinib given alone would be safe and effective to treat patients with inflammatory breast cancer."
Currently there are just two sites in the U.S. recruiting for the trial, and an additional site is pending. To study the inclusion/exclusion criteria and available sites for this trial (NCT00558102) visit: ClinicalTrials.gov. (http://r20.rs6.net/tn.jsp?llr=rpzyw687&et=1103828849689&s=3451&e=001v52O4DI7Y8B9N1cpMA73MiOwVUPNU0DDvPvM7ZhsaFLxU fbj8IVG8rH6rh_Z5pvCvcWajxzDLmUVOYvEmfN-brFzlNm_N3jaTkRaTQvp8hJ0Jii1hgLj3sSS1u2XpcOnQnp5Oa nRgQLh9NyBp6HWPFAdR3nH-vKDHYVOSIKOWRz3QY2QaOJUaWmkUFuhrnTJNxzCgstDnqhon7l kLUnZeN1oSckMrkkfj9PA1R2SfEgrD5XIEVyDP-Z_xZlTs9l3lDMt1tlu2DWBee8nhC_5tQ==)
**The above is informational only and should not be considered a recommendation or endorsement of any specific clinical trial by the Inflammatory Breast Cancer Research Foundation.